Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Xu, Yang ^a,b   Liu, Zhen ^a   Sun, Jie ^a   Pan, Qiangrong ^a   Sun, Feifei ^a   Yan, Zhiyu ^a   Hu, Xun ^a  

^a China National Ministry of Education   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; SCHIZANDRIN B; ANTINEOPLASTIC AGENT; CYCLOOCTANE DERIVATIVE; GLUTATHIONE; LIGNAN; POLYCYCLIC HYDROCARBON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CARDIOTOXICITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG POTENTIATION; HEART FUNCTION TEST; HEART LEFT VENTRICLE; HEART PROTECTION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; MONOTHERAPY; MOUSE; NONHUMAN; RAT; SARCOMA CELL; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; HEART; HEART MUSCLE; HEART VENTRICLE; METABOLISM; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOLOGY; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOCTANES; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; GLUTATHIONE; HEART; HEART VENTRICLES; LIGNANS; MALE; MICE; MICE, INBRED BALB C; MYOCARDIUM; OXIDATION-REDUCTION; OXIDATIVE STRESS; POLYCYCLIC COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 82555187159     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028335     Document Type: Article

References (38)

1. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.
2. Fogli S, Nieri P, Breschi MC, (2004) The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. Faseb J 18: 664-675.
3. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE, (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131: 561-578.
4. Peng X, Chen B, Lim CC, Sawyer DB, (2005) The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Mol Interv 5: 163-171.
5. Doroshow JH, Locker GY, Myers CE, (1980) Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 65: 128-135.
6. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK, (1995) Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 91: 10-15.
7. Li T, Singal PK, (2000) Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 102: 2105-2110.
8. Siveski-Iliskovic N, Kaul N, Singal PK, (1994) Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 89: 2829-2835.
9. Ip SP, Poon MK, Che CT, Ng KH, Kong YC, et al. (1996) Schisandrin B protects against carbon tetrachloride toxicity by enhancing the mitochondrial glutathione redox status in mouse liver. Free Radic Biol Med 21: 709-712.
10. Yim TK, Ko KM, (1999) Schisandrin B protects against myocardial ischemia-reperfusion injury by enhancing myocardial glutathione antioxidant status. Mol Cell Biochem 196: 151-156.
11. Ko KM, Yiu HY, (2001) Schisandrin B modulates the ischemia-reperfusion induced changes in non-enzymatic antioxidant levels in isolated-perfused rat hearts. Mol Cell Biochem 220: 141-147.
12. Ko KM, Lam BY, (2002) Schisandrin B protects against tert-butylhydroperoxide induced cerebral toxicity by enhancing glutathione antioxidant status in mouse brain. Mol Cell Biochem 238: 181-186.
13. Li L, Pan Q, Han W, Liu Z, Li L, et al. (2007) Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling. Clin Cancer Res 13: 6753-6760.
14. Hu X, (2006) Application of dibenzocyclooctadiene lignans in preparation of medicine against side effects of anticancer drugs. China patent: application number 200610111123.200610111128.
15. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, et al. (2008) Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 26: 3777-3784.
16. Li L, Lu Q, Shen Y, Hu X, (2006) Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells. Biochem Pharmacol 71: 584-595.
17. Li L, Pan Q, Sun M, Lu Q, Hu X, (2007) Dibenzocyclooctadiene lignans: a class of novel inhibitors of multidrug resistance-associated protein 1. Life Sci 80: 741-748.
18. Qiangrong P, Wang T, Lu Q, Hu X, (2005) Schisandrin B-a novel inhibitor of P-glycoprotein. Biochem Biophys Res Commun 335: 406-411.
19. Hu X, Wang T, (2004) Application of schisandrin B in the preparation of medicine against cancer. China Patent zl200410059607.200410059603.
20. Fong WF, Wan CK, Zhu GY, Chattopadhyay A, Dey S, et al. (2007) Schisandrol A from Schisandra chinensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp-substrate complexes. Planta Med 73: 212-220.
21. Pulaski BA, Ostrand-Rosenberg S, (2001) Mouse 4T1 breast tumor model. Curr Protoc Immunol Chapter 20: Unit 20 22.
22. Pan Q, Lu Q, Zhang K, Hu X, (2006) Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 58: 99-106.
23. Sun M, Xu X, Lu Q, Pan Q, Hu X, (2007) Schisandrin B: a dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1. Cancer Lett 246: 300-307.
24. Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, et al. (2009) Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 119: 99-106.
25. Cusack BJ, Tesnohlidek DA, Loseke VL, Vestal RE, Brenner DE, et al. (1988) Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. Cancer Chemother Pharmacol 22: 294-298.
26. Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE, (1983) Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res 43: 3417-3421.
27. Winyard PG, Moody CJ, Jacob C, (2005) Oxidative activation of antioxidant defence. Trends Biochem Sci 30: 453-461.
28. Chen N, Ko M, (2010) Schisandrin B-induced glutathione antioxidant response and cardioprotection are mediated by reactive oxidant species production in rat hearts. Biol Pharm Bull 33: 825-829.
29. Chiu PY, Chen N, Leong PK, Leung HY, Ko KM, (2011) Schisandrin B elicits a glutathione antioxidant response and protects against apoptosis via the redox-sensitive ERK/Nrf2 pathway in H9c2 cells. Mol Cell Biochem 350: 237-250.
30. Yoshida M, Shiojima I, Ikeda H, Komuro I, (2009) Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J Mol Cell Cardiol 47: 698-705.
31. Nishida H, Tatewaki N, Nakajima Y, Magara T, Ko KM, et al. (2009) Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response. Nucleic Acids Res 37: 5678-5689.
32. Kelland LR, (2004) Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 40: 827-836.
33. Varvaresou A, Iakovou K, Gikas E, Fichtner I, Fiebig HH, et al. (2004) Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo. Anticancer Res 24: 907-919.
34. Huang M, Jin J, Sun H, Liu GT, (2008) Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. Cancer Chemother Pharmacol 62: 1015-1026.
35. Wan CK, Zhu GY, Shen XL, Chattopadhyay A, Dey S, et al. (2006) Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells. Biochem Pharmacol 72: 824-837.
36. Sacco G, Giampietro R, Salvatorelli E, Menna P, Bertani N, et al. (2003) Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity. Br J Pharmacol 139: 641-651.
37. Kang YJ, Chen Y, Yu A, Voss-McCowan M, Epstein PN, (1997) Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Invest 100: 1501-1506.
38. Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, et al. (2002) Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 300: 862-867.